Research of Yiqi Huadu Decoction United Cinobufagin Bladder Irrigation Control Postoperative Recurrence of Superficial Bladder Cancer

CUI Dian-sheng; XIONG Zhi-guo; YIN Tao; WEI Shao-zhong

doi:10.13422/j.cnki.syfjx.2014160204

您当前的位置：

首页 >

文章列表页 >

Research of Yiqi Huadu Decoction United Cinobufagin Bladder Irrigation Control Postoperative Recurrence of Superficial Bladder Cancer

更新时间：2024-01-04

- Research of Yiqi Huadu Decoction United Cinobufagin Bladder Irrigation Control Postoperative Recurrence of Superficial Bladder Cancer
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 20, Issue 16, Pages: 204-208(2014)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2014160204
  CLC： R737.14
- Published：2014
- 稿件说明：
移动端阅览
CUI Dian-sheng, XIONG Zhi-guo, YIN Tao, et al. Research of Yiqi Huadu Decoction United Cinobufagin Bladder Irrigation Control Postoperative Recurrence of Superficial Bladder Cancer[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(16): 204-208.
DOI：

CUI Dian-sheng, XIONG Zhi-guo, YIN Tao, et al. Research of Yiqi Huadu Decoction United Cinobufagin Bladder Irrigation Control Postoperative Recurrence of Superficial Bladder Cancer[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(16): 204-208. DOI： 10.13422/j.cnki.syfjx.2014160204.

摘要

目的：观察益气化毒方内服联合华蟾素膀胱灌注防治浅表性膀胱癌术后复发的防治作用及对患者细胞免疫功能和血清血管内皮生长因子（VEGF）的影响。方法：将90例患者随机按数字表法分为西药组和观察组各45例。两组均采用经尿道膀胱肿瘤切除术（TUR-BT），术后西药组给予盐酸吡柔比星，30 mg/次，膀胱灌注，1次/周，共8次，以后1次/月，共10次，疗程共12个月。观察组采用华蟾素注射，30 mL/次，和盐酸吡柔比星，30 mg/次，膀胱灌注，方法及疗程均同西药组；同时内服益气化毒方，前3个月每日1剂，此后隔日1剂。两组疗程均为12个月。采用B超、膀胱镜等检测患者术后1年内复发情况；采用流式细胞仪法检测治疗前后3，6个月外周血T淋巴细胞亚群（CD3+，CD4+，CD8+和CD4+/CD8+）和自然杀伤细胞（NK）水平；检测治疗前后3，6，12个月血清血管内皮生长因子（VEGF）水平；记录治疗前后3，6，12个月生存质量（KPS）评分；记录不良反应，如恶心、呕吐、腹痛、腹泻等情况，并监测肝功能及血常规。结果：术后1年内观察组复发7例，复发率15.56%，西药组复发15例，复发率33.33%，观察组复发率低于西药组（P<0.05）；治疗后6个月，观察组CD3+，CD4+，CD4+/CD8+和NK细胞水平高于西药组，CD8+水平低于西药组（P<0.01）；治疗后3个月，西药组KPS评分较治疗前下降（P<0.05），观察组变化不明显；治疗后3，6，12个月观察组KPS评分均高于西药组（P<0.05，P<0.01）；治疗后6，12个月观察组血清VEGF水平低于西药组（P<0.01）；西药组不良反应累积发生26例，发生率为57.7%，观察组为15例，发生率为33.3%，观察组不良反应累积发生率低于西药组（P<0.05）。结论：华蟾素膀胱灌注联合益气化毒方内服能进一步降低浅表性膀胱癌TUR-BT术后患者的复发率，能减轻化疗药物所致的不良反应，提高患者生活质量，其作用机制可能与提高患者细胞免疫功能，降低血清VEGF水平有关。

Abstract

Objective: The observe taken orally the Yiqi Huadu decoction which combined with cinobufagin Bladder irrigation to prevent and cure postoperative recurrence of superficial bladder cancer to survey the influence of patients' cellular immune function and vascular endothelial growth factor(VEGF). Method: Ninety patients were randomly divided into western medicine group (45 cases) and observation group (45 cases) by random number method. Both group adopt urinary bladder tumor resection (TUR-BT).After the surgery

the patients in western medicine group took pirarubicin hydrochloride

30 mg/time

once a week

by bladder perfusion

8 times in total.Since then

1 time in a month

10 times in total.Treatment courses were 12 months.Use Huachan hormone injections (30 mL/time)and pirarubicin hydrochloride (30 mg/time)by bladder perfusion for observation group.The methods and treatment were the same as the western medicine group.In the meantime

observation group patients added Yiqi Huadu decoction

one does a day in the first three months.Since then

took a potion in interval one day.The total treatment courses were 12 months.Using B ultrasound and cystoscope et to detect patients' relapse within a year.Adopt flow cytometry instrument method test the level of peripheral blood T lymphocyte subsets(CD3+

CD4+

CD8+和CD4+/CD8+)and natural killer cells(NK) at the third

sixth and twelfth month before and after treatment.Detect the level of vascular endothelial growth factor(VEGF) and record quality of life (KPS) score at the third

sixth and twelfth month before and after treatment.Record adverse reactions

such as nausea

vomiting

abdominal pain

diarrhea

etc.Besides monitor the liver function and blood routine. Result: During one year after operation

numbers of relapsing cases in observation group were 7 and the rate was 15.56%

numbers of relapsing cases in western medicine group were 15

and the rate was 33.33%

and rate of relapsing cases in observation group was lower than in western medicine group(P<0.05).At the sixth mouth after treatment

levels of CD3+

CD4+

CD4+/CD8+ and NK in observation group were higher than those in western medicine group(P<0.01)

and level of CD8+ was lower than in western medicine group(P<0.01).After three mouths of treatment

compared with the time before treatment

score of KPS in observation group decreased(P<0.05)

which in western medicine group was not significant.After three

six and twelve mouths of treatment

scores of KPS in observation group were higher than those in western medicine group(P<0.05

P<0.01).After six and twelve mouths of treatment

levels of serous VEGF in observation group were lower than those in western medicine group(P<0.01).Cumulative happened of adverse reactions in western medicine group were 26 cases

and the rate was 57.7%

cumulative happened of adverse reactions in observation group were 15 cases

and the rate was 33.3%

which in observation group were lower than those in western medicine group(P<0.05). Conclusion: Cinobufacini bladder perfusion combined with oral Yiqi flower and reduce the recurrence of bladder cancer after operation

reduce the adverse reaction induced by chemotherapy

improve the quality of life

and its mechanism may be related to improving cellular immune function of patients

reduce the level of serum VEGF.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of Shengbao Granula on Immunological Function in Mice with Immunological Deficiency

Hainan Herba Hedyotis Effect on 'Cancerous Toxin' of Primary Liver Cancer

Related Author

HE Fei

SU Hua

WEI Gui-ning

LUO Xin

QI Qi

Related Institution

No data

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰